CROSS-DOMAIN PATTERN
Same drug, multiple disease domains
pembrolizumab appears in hypotheses across 4 disease domains: ALS, Glioblastoma, Inflammatory bowel disease, Pancreatic cancer. Shared mediators that recur across at least two of those domains: PD-1.
Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.
ALL HYPOTHESES
Repurposing candidates for pembrolizumab
ALS 3
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| PD-1 | unfavorable prognosis | 0.230 | Mid | reproduces known | none | |
| PD-1 | ALS disease progression | 0.230 | Mid | novel signal | none | |
| PD-1 | ALS | 0.230 | Mid | partial evidence | none |
Glioblastoma 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| PD-1 | glioblastoma growth | 0.230 | Mid | novel signal | completed |
Inflammatory bowel disease 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| PD-1 | PD-1 inhibitor-associated colitis | 0.230 | Mid | novel signal | none |
Pancreatic cancer 4
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| PD-1 | advanced T stage | 0.230 | Mid | novel signal | active | |
| PD-1 | pancreatic cancer | 0.230 | Mid | reproduces known | active | |
| PD-1 | prognosis | 0.230 | Mid | reproduces known | active | |
| PD-1 | lymph node metastasis | 0.230 | Mid | reproduces known | completed |